Stock CMPS COMPASS PATHWAYS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases COMPASS Pathways plc

Equities

CMPS

US20451W1018

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-20 EDT 		5-day change 1st Jan Change
6.32 USD -1.71% Intraday chart for COMPASS Pathways plc -8.93% -27.77%
06-05 Morgan Stanley Adjusts COMPASS Pathways Price Target to $23 From $30, Maintains Overweight Rating MT
06-04 FDA panel to review psychedelic drug MDMA for first time RE

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
COMPASS Pathways : 2024 AGM Voting Results
PU
Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights
GL
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
GL
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
GL
Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression
GL
Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
GL
COMPASS Pathways : Presentation – March 2024
PU
Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights 
GL
Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved
GL
Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved
AQ
Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement
GL
Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement
AQ
Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder
GL
Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder
AQ
Compass Pathways appoints Teri Loxam as Chief Financial Officer
GL
Compass Pathways appoints Teri Loxam as Chief Financial Officer
AQ
Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry
GL
Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center
GL
COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights
GL
COMPASS Pathways announces CFO transition
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CMPS Stock
  4. News COMPASS Pathways plc
  5. Press Releases